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Ischemia–reperfusionMesenteric lymph pathway serves as the primary route by which gut injury leads to systemic inﬂammation and
distant organ injury. The inﬂammation of the intestinal tract is partiallymediated by vasoactive intestinal peptide
(VIP). Therefore, the aim of this studywas to testwhether exogenous VIP affectsmesenteric lymph pathway dur-
ing early intestinal ischemia–reperfusion (IIR) injury. Rats were randomized into control, control + VIP, IIR and
IIR + VIP groups. The observation of mesenteric lymph ﬂow was carried out by cannulation of mesenteric lym-
phatics. The distribution of in vivo lymphocyte trafﬁcking was performed by 51Cr labeled lymphocytes and was
measured by γ-counter. Endotoxin concentration was assayed using the limulus test kit and TNF-α level was de-
tected by ELISA. When IIR injury treated with VIP, the volumes of lymph ﬂow increased by 80%, which caused
the number of lymphocytes exiting in mesenteric lymphatic increased by 50% while the proportion of 51Cr-
lymphocytes in Peyer's patches, intestinal effector tissues, mesenteric nodes, large intestine, stomach decreased
by 58%, 51%, 58%, 63%, 64% respectively at the 6th h after reperfusion following intestinal ischemia. Meanwhile,
endotoxin and TNF-α levels in intestinal lymph decreased by 51% and 83%. These results suggest that exogenous
VIP ameliorates IIR induced splanchnic organ damage via inhibition of toxic mediators reaching systemic circu-
lation and reinforcement of the effective immune responses in gut-associated lymphoid tissues (GALT).
Crown Copyright © 2013 Published by Elsevier B.V. All rights reserved.1. Introduction
Vasoactive intestinal peptide (VIP) is a 28-amino acid peptide be-
longing to the members of a superfamily of structurally related peptide
hormones with a broad range of biological activities [1]. It has been
found in high concentrations both in the central nervous system and
gastrointestinal tract [2]. Many studies have reported that VIP plays an
important role in immune regulation [3–5] in an anti-inﬂammatory
manner [6,7], including inhibition of the endotoxin induced TNF-α
production by macrophages [8], the release of IL-6 from macrophages
stimulated with high lipopolysaccharide doses [9], and the expression
and secretion of IL-2, IL-4, and IL-10 in stimulated peripheral T cell
[10]. In addition, VIP attenuates small intestinal microcirculation and
mucosal injury after hepatic ischemia–reperfusion (IR) [11], hepatic
microvasculatory disturbances following intestinal IR (IIR) [12], and IR
injury in orthotopic mouse lung transplants [13], However, the exact
mechanism is still unknown.erms of the Creative Commons
whichpermits non-commercial
d the original author and source
gy,West ChinaHospital, Sichuan
China. Tel.: +86 28 85422383;
Published by Elsevier B.V. All rightsIIR injury occurs in various clinical critical illnesses leading to high
morbidity and mortality [14,15]. It triggers an intense inﬂammatory re-
sponse that results systemic inﬂammatory response syndrome (SIRS)
and evenmultiple organ dysfunction syndrome (MODS) [15–17]. During
IIR injury, various injurious toxic mediators produced in ischemic areas
enter the circulation and lead to distant organ (including the lung,
liver, heart and kidney) damage [18,19]. Mesenteric lymph pathway
(i.e., mesenteric lymph leaving mesenteric efferent lymphatic enters
the subclavian vein via the thoracic duct, which, in turn, empties directly
into other organs) serves as the primary route for the injurious gut-de-
rived toxic factors, which can induce SIRS and MODS [20,21]. These
toxic factors have been demonstrated in mesenteric lymph, but not in
the systemic or portal circulation [22]. Additionally, the continual traf-
ﬁcking of numerous activated intestinal lymphocytes from mesenteric
lymph to systemic circulation are to ensure antigenic encounter and
the triggering of the effective immune responses [23,24]. Therefore,mes-
enteric lymph pathway plays a more crucial role from IIR injury to SIRS
and evenMODS. To our knowledge, there are no data available regarding
the roles of mesenteric lymph pathway in the effects of VIP on IIR injury.
The objectives of the present study are to observe the effects of VIP
on the disorders of mesenteric lymph ﬂow and in vivo intestinal lym-
phocyte trafﬁcking and the levels of certain gut-derived toxic factors
in the mesenteric lymph after IIR injury, and to highlight on the role of
VIP in IIR induced splanchnic organ dysfunction in view of the interac-
tion between gut peptides and mucosal immunity.reserved.
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2.1. Experimental grouping and VIP treatment
Forty-eight healthy adult male Wistar rats weighing 250–300g
were provided by the experimental animal center of Nanjing Medical
University, China. The following experimental groups were included
in this study: 1) normal control (sham-operation) group1 (n = 6),
2) control + VIP group1 (n = 6), 3) IIR group1 (n = 6), 4) IIR + VIP
group1(n = 6), 5) normal control group2 (n = 6), 6) control + VIP
group2(n = 6), 7) IIR group2 (n = 6), and 8) IIR + VIP group2
(n = 6). In group1, the volumes of mesenteric lymph and the number
of intestinal lymphocytes output in the mesenteric lymphatic at
the 6th h after reperfusion were observed and in group2, 51Cr labeled
intestinal lymphocytes in vivo trafﬁcking in vital organs at the same pe-
riod of time were countered. VIP-28 (Calbiochem, EMD Bioscience, La
Jolla, CA, USA) was given to femoral vein of rats at a dosage of
0.2 ρmol/g/h from 30 min before occlusion of the superior mesenteric
artery (SMA) until the end of the experiment with a syringe pump
(B. Braun Co. Germany) combined with intraperitoneal injection at a
dosage of 0.25 ρmol/g from 30 min, 0 min before occlusion of the
SMA and 120 min, 240 min after occlusion of the SMA. In the control
group or the IIR group, 0.9% saline water instead of VIP was injected
into femoral vein of rats according to the same procedure as rats with
VIP treatment. All procedures using animals were reviewed and ap-
proved by the Experimental Animal Review Board of Nanjing Medical
University and were performed according to the criteria outlined by
the National Ministry of Health.
2.2. Surgical procedure
The superior mesenteric artery (SMA) of rats in the IIR groupwas li-
gated with a small clamp until complete ischemia of SMA for 45 min.
Upon release of the clamp, the rats were allowed recovering from anes-
thesia for 6 h. After reperfusion, the rats were sacriﬁced under deep
isoﬂurane anesthesia. In the normal control group, the SMAwas isolated
without clamping and was exposed to the same procedure as rats with
SMA occlusion.
2.3. Mesenteic lymph collection and lymphocytes counting
The procedures used to collect the mesenteric lymph in rats have
been described previously [25]. Brieﬂy, the rats were anesthetized
with amobarbital by intraperitoneal injection. Amidline celiotomy inci-
sionwasmade and themesenteric lymphatic identiﬁed (adjacent to the
SMA) by reﬂecting the loops of intestine to the left of the animal with a
metal hook. A plastic tube, 1 mm in diameter, with beveled ends, was
passed into themesenteric lymphatic and the lymph begins to ﬂow im-
mediately through the tubes. The lymphatic was divided with visible
conﬁrmation of free ﬂow of lymph into a centrifuge tube. After collec-
tion stopped, the mesenteric lymph was measured and lymphocytes
were counted under light scope.
2.4. T and B lymphocytes counting in mesenteric lymph
Intestinal lymphocytes were collected as described above. Cell via-
bility was determined by 0.2% Evans blue staining. More than 95% of
the cells were viable for measurement of lymphocyte subsets. CD3T,
CD20 B lymphocyte subsets were analyzed by ﬂow cytometry.
2.5. Determination of in vivo lymphocyte trafﬁcking
In group2, mesenteric lymph was collected for 1 h in the 4th h after
reperfusion. Then, the lymphocytes collected frommesenteric lymphat-
ic were labeledwith 51Cr and infused into femoral vein of rats at the be-
ginning of the 6th h after reperfusion. 1 h later, the rats were killed,small intestines containing 51Cr-intestinal lymphocytes and other vital
organs were removed and counted with γ-counter.2.6. Intestinal lymphocyte labeled with 51Cr
1 × 107 lymphocytes/mL in RPMI 1640 (containing 20% fetal bovine
serum) were incubated with 20 μCi/mL Na2[51Cr]O4 for 1 h at 37°C in
water. After incubation, the liquid was centrifuged at 500 g for 5 min,
then the supernatant was decanted and the remainder was added into
a test tube containing 100% fetal bovine serum and 17% Nycodenz
(Sigma Co. USA). The mix liquid was centrifuged at 1200 g for 5 min.
The 51Cr labeled lymphocytes were collect from the layer between
fetal bovine serum and Nycodenz. 5 × 106 51Cr-lymphocytes mixed
with 0.4 mL of RPMI-1640 were infused slowly into the femoral vein
of rats. 1 h later, rats were killed and the small intestines and other
vital organs were removed and 1 mL of blood sample was taken from
heart puncture. The organs containing 51Cr labeled lymphocytes were
measured by γ-counter (TDC-601, Aloka Co, Japan) [26]. The total
counts of the 1 × 107 lymphocytes were measured and lymphocyte
populations in the intestine and other organswere calculated as a back-
ground corrected percentage of counts per organ over the total counts.2.7. Functinonal evaluation of vital organs
Peripheral bloodwas taken from rats in each group before theywere
killed to determine the oxygen partial pressure (PaO2) with DMNI
modular system (AVL, Graz, Austria), alanine aminotransferase (ALT),
and creatinine level (AUOLYMPUS5400; Olympus, Tokyo, Japan). Plas-
ma D-lactate concentration wasmeasured by an enzymatic spectropho-
tometric assay using a centrifugal analyzer at 30°C (Hoffmann-LaRoche,
Basle, Switzerland) as described earlier [27]. D-lactate, D-lactate dehy-
drogenase and NAD+ were purchased from Sigma Chemical Company
(USA).2.8. Measurement of endotoxin concentration and TNF-α activity
Endotoxin concentration in plasma ormesenteric lymphwas assayed
using the limulus test kit (Yihua Clinical Technology Co, Shanghai,
China). The assay depends on bacterial endotoxin to activate a proen-
zyme in the limulus amoebocyte lysate that catalyzes the cleavage of
p-nitroaniline (pNA) from the colorless substrate. The pNA is assayed
spectrophotometrically at 545 nm and provides a quantitative analysis
of endotoxin content. TNF-α concentration in serum and mesenteric
lymph was determined by using rat TNF-enzyme-linked immuno-
absorbent assay (ELISA) kit (LIFEKEY Biotech, Co. USA) according to
manufacturer's protocol.2.9. Morphological changes of the gut and injury score
Specimens from the small intestines (5 cm from the distal end of
ileum) were taken out and ﬁxed with 10% formaldehyde. The parafﬁn
sections were stained with hematoxylin and eosin for histological eval-
uation in a single blinded fashion. For semiquantitative evaluation of
lesions, 10 arbitrary microscopic ﬁelds were viewed in each sample.
The scoring system was based on area of the lesion: +, b1/3 total
area; ++, 1/3–2/3 total area; +++, N2/3 total area.2.10. Statistical analysis
All data were expressed as the means ± standard deviation (SD).
Statistical analysis was performed by one-way ANOVA with Fisher's
test. Difference was considered statistically signiﬁcant when p b0.05.
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3.1. Pathological changes of the intestine and injury score
During IIR injury, the intestinal villi were loosened and atrophic
where the epithelial cells were necrotic. The mucosa was edematous
and inﬁltratedwith inﬂammatory cells (Fig. 1B). Semiquantitative eval-
uationwas scored as++. After IIR injury treatedwith VIP, the intestinal
mucosa and the villi recovered completely. Semiquantitative evaluation
was scored as +.
3.2. Functinal changes of vital organs or tissues
After IIR injury treatedwith VIP, plasmaD-lactate, ALT and creatinine
levels decreased by 57% ([7.17 ± 0.55] μg/mL vs [11.28 ± 1.1] μg/mL,
p b 0.05, Fig. 2A), 55% ([115 ± 33] U/L vs [258 ± 57] U/L, p b 0.05,
Fig. 2B), 30% ([61.50 ± 13.32] μmol/L vs [87.68 ± 25.61] μmol/L,
p b 0.05, Fig. 2C) respectively, when compared with those in IIR group1.
PaO2 in IIR + VIP group1 increased by 63% ([16.787 ± 3.596] kPa vs
[10.284 ± 1.354] kPa, p b 0.05, Fig. 2D) compared with those in IIR
group1.
3.3. Changes of endotoxin and TNF-α levels
There were signiﬁcant differences of endotoxin levels between
IIR group1 and normal control group1 in mesenteric lymph ([0.054 ±
0.032] EU/mL vs [0.108 ± 0.021] EU/mL, p b 0.05) and plasma
([0.228 ± 0.071] EU/mL vs [0.452 ± 0.135] EU/mL, p b 0.05) as shown
in Fig. 3A. Meanwhile, TNF-α levels in mesenteric lymph ([12.50 ±
7.22] ρg/mL) and serum ([28.75 ± 10.46] ρg/mL) in IIR + VIP group1
signiﬁcantly decreased (p b 0.05, Fig. 3B) compared with those in IIR
group1 ([70.35 ± 14.12] ρg/mL in mesenteric lymph and [48.21 ±
8.59] ρg/mL in serum).
3.4. Changes of mesenteric lymph ﬂow and counting of lymphocytes
The number of intestinal lymphocytes in mesenteric lymph at the
6th h after mesenteric reperfusion signiﬁcantly increased in IIR + VIP
group1 compared with that in IIR group1 ([0.42 ± 0.18] × 107/h vs
[0.25 ± 0.12] × 107/h, p b 0.05, Fig. 4C), which caused by the increases
of mesenteric lymph volume at the same period of time ([0.45 ±
0.11] mL/h vs [0.28 ± 0.11]mL/h, p b 0.05, Fig. 4A). The number of in-
testinal lymphocytes per milliliter had no signiﬁcant differences
between both groups ([0.93 ± 0.12] × 107/mL vs [0.89 ± 0.13] ×
107/mL, p b 0.05, Fig. 4B), while the proportion of T cell subsets in
IIR + VIP group1 markedly increased ([67.40 ± 5.03]% vs [52.00 ±
3.41]%, p b 0.05, Fig. 4D) and the population of B cell subsets in
IIR + VIP group1 signiﬁcantly decreased compared with those in IIR
group1([27.40 ± 4.50]% vs [38.20 ± 2.02]%, p b 0.05, Fig. 4D).Fig. 1. The obvious improvement of histologieswas observed in the rats subjected to IIR treated
×100). Representative slide from the intestinal tissues (5 cm from the distal end of the ileum) o
and captured under a light microscope.3.5. Change of in vivo lymphocyte trafﬁcking
After IIR injury treatedwith VIP, proportion of intestinal 51Cr-lympho-
cytes in Peyer's patches ([2.14 ± 1.49]% vs [4.94 ± 1.15]%, p b 0.05), in-
testinal effector tissues including intraepithelial space (IEL) and lamina
propria (LP) ([1.58 ± 0.42]% vs [3.30 ± 1.58]%, p b 0.05), mesenteric
nodes ([1.38 ± 0.60]% vs [3.25 ± 0.65]%, p b 0.05), large intestine
([1.14 ± 0.83]% vs [3.02 ± 1.64]%, p b 0.05), and stomach ([0.75 ±
0.51]% vs [2.05 ± 1.19]%, p b 0.05) signiﬁcantly decreased in IIR group2.
There were no signiﬁcant differences between IIR + VIP group2 and
IIR group2 in blood ([11.83 ± 3.97]% vs [11.05 ± 3.70] %, p N 0.05),
liver ( [28.89 ± 7.09]% vs [27.22 ± 9.25]%, p N 0.05), spleen ([15.40 ±
1.75]% vs [14.19 ± 5.35] %, p N 0.05), lung ([21.34 ± 9.09]% vs
[22.70 ± 8.14]%, p N 0.05) and kidney ([1.88 ± 0.33]% vs [2.08 ±
0.23]%, p N 0.05, Fig. 5) compared with those in IIR group2.
4. Discussion
Clinical care illnesses including shock, infection, severe acute pan-
creatitis, and organ transplantation are susceptible to IIR injury [28].
Reperfusion of the intestine subjected to ischemia or hypoperfusion of
intestinal tissues results in an increase in intestinal inﬂammation and
loss of intestinal barrier function as the initial triggering events that con-
tribute to the development of SIRS [29,30]. However, inﬂammation of
the intestinal tract may be partially mediated by gut peptides or neuro-
transmitters [31,32]. VIP exerts therapeutic effects by acting as a potent
anti-inﬂammatory factor in many different disease models, including
septic shock, inﬂammatory bowel disease, and acute lung injury
[33–35]. After IIR injury treated with VIP, the signiﬁcant improvements
of pathological changes were observed in this study. This ﬁnding sug-
gests that VIP reduces the severity of intestinal histopathologic changes
(Fig. 1). Additionally, the plasma D-lactate levels decreased after intra-
venous injection combined with intraperitoneal injection of VIP in rats
subjected to IIR injury (Fig. 2). D-lactate is produced by bacteria of the
gastrointestinal tract and is absorbed in the small intestine and colon
and plasma and is a sensitive marker for gut barrier failure [27]. This in-
dicates that VIP promotes the recovery of intestinal barrier function.
Meanwhile, the plasma aminoleucine transferase (ALT) and creatinine
levels decreased and blood PaO2 pressure increased (Fig. 2). It suggests
that VIP improveds the functional damage of the liver, the kidney and
the lung.
Gut-derived factors carried in themesenteric lymph as the source of
factors leading to lung and heart injuries as well the induction of SIRS
after burn injury or trauma–hemorrhage [36,37]. However, the exact
factors responsible for triggering this inﬂammatory cascade leading to
remote organ dysfunction have not been known completely [38]. Evi-
dences indicate that gut-derived endotoxin and TNF-α are the impor-
tant mediators involved in activating the inﬂammatory reactions and
potentiate the development of MODS [38,39]. After IIR injury treatedwith VIP(C). Histological changes of ileum from three groups (hematoxylin and eosin stain,
f rats subjected to IIR (B) or IIR treatedwith VIP (C) or sham operation (A)were visualized
Fig. 2. Quantiﬁcation of vital parameters of organic function in rats. A. D-lactate, B. ALT, C. creatinine, D. PaO2. *p b 0.05 compared with control group1, #p b 0.05 compared with
control + VIP group1, †p b 0.05 compared with IIR group1.
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cantly decreased while the TNF-α levels in intestinal lymph and
serum decreased at the 6th h after reperfusion compared with those
in IIR group in this study (Fig. 3). This suggests that VIP can suppress
an increased inﬂammatory response caused by IIR injury via inhibition
of endotoxin generation and TNF-α production.
The mesenteric lymphmicrocirculation forms an important route to
return the lymph fromgut-associated lymphoid tissues (GALT) to blood
circulation. In the clinical setting, mesenteric lymph pathway can be
disrupted bymanydifferent causes including infection, trauma, surgery,
shock, and radiation [18]. Meanwhile, lymphocytes, particularly T cells
have an important role during IIR injury. There are evidences showedFig. 3. Changes of endotoxin (A) and TNF-α (B) levels inmesenteric lymph and peripheral blood
group1, †p b 0.05 compared with IIR group1.that signiﬁcant T-cell adhesion in mucosal venule of the postischemic
intestine was noted at the 6th h after reperfusion [40]. Fukatsu K et al.
[41] demonstrated that IIR signiﬁcantly reduced the number of intesti-
nal intraepithelial lymphocytes and lymphocytes in Peyer's patches
(PP) and the lamina propria (LP). During IIR injury, the number of intes-
tinal lymphocytes exiting in mesenteric efferent lymphatic at the 6th h
after mesenteric reperfusion signiﬁcantly decreased (predominantly T
cells) compared with those in control group, which caused by the re-
duced mesenteric lymph ﬂow at the same period of time as a result of
hypoperfusion of the ischemic intestinal tissues and the decreased
number of intestinal lymphocytes per milliliter because of reduction
in generation of lymphocytes in the ischemic GALT (Fig. 4). The reducedin rats. *p b 0.05 comparedwith control group1, #p b 0.05 comparedwith control + VIP
Fig. 4. Changes of the volumes of mesenteric lymph and the number of intestinal lymphocytes exiting in mesenteric lymphatic at the 6th h after reperfusion in rats. A. Volumes of mes-
enteric lymph at the 6th h after reperfusion (mL/h). B. Number of intestinal lymphocytes output permilliliter ofmesenteric lymph (107/mL). C. Number of intestinal lymphocytes output at
the 6th h after reperfusion (107/h). D. Percentage of lymphocyte subsets of intestinal lymphocytes output at the 6th h after reperfusion (%). *p b 0.05 compared with control group1,
#p b 0.05 compared with control + VIP group1, †p b 0.05 compared with IIR group1.
40 H. Yang et al. / Regulatory Peptides 186 (2013) 36–42volumes of lymph ﬂow and the decreased intestinal lymphocytes
exiting in mesenteric efferent lymphatic at the 6th h of reperfusion
as an early response to IIR injury showed the disturbances of the mes-
enteric lymph after reperfusion. Furthermore, we deduce that the
number of intestinal lymphocytes migration from blood circulation
to gastroenteric tract will decrease as a result of the reduced number
of lymphocytes exiting in mesenteric efferent lymphatic. However,
the proportion of 51Cr-intestinal lymphocytes in gastroenteric tractFig. 5. Changes of in vivo trafﬁcking of 51Cr labeled intestinal lymphocytes at the 6th h after
control + VIP group2, †p b 0.05 compared with IIR group2.signiﬁcantly increased at the same period of time (Fig. 5). A possible ex-
planation for the fact that IIR-induced increase in the proportion of 51Cr-
lymphocytes in digestive tractmay be considered as a compensatory re-
sponse for the limitation of the intestinal lymphocytes recirculation
back through GALT and may not increase the overall number of intesti-
nal lymphocytes migration from systemic circulation to gastrointestinal
mucosa and improve the mucosal immune function. When IIR injury
treated with VIP, although the number of intestinal lymphocytes perreperfusion in rats. *p b 0.05 compared with control group2, #p b 0.05 compared with
41H. Yang et al. / Regulatory Peptides 186 (2013) 36–42milliliter had no changes, the volumes of lymph ﬂow at the 6th h after
mesenteric reperfusion obviously increased, which caused the number
of intestinal lymphocytes output signiﬁcantly increased (Fig. 4) Mean-
while, the proportion of 51Cr-lymphocytes in PP, intestinal effector tis-
sues (including IEL and LP), mesenteric nodes, large intestine, and
stomach sharply decreased compared with those in IIR group (Fig. 5).
For this observation, we may speculate that VIP prevents gut-derived
toxic mediators reaching the systemic circulation because of the endo-
toxin and TNF-α concentration in mesenteric lymph markedly de-
creased (Fig. 3), although the volumes of mesenteric lymph ﬂow at
the 6th h after mesenteric reperfusion enhanced by VIP increase the
amount of these toxic factors reaching system circulation, which is not
relatively dominant comparedwith their obvious reduction in themes-
enteric lymph. On the other hand, intestinal lymphocytes reaching
blood circulation and in turn homing to the effector sites of GALT includ-
ing IEL and LP increased due to the number of lymphocytes exiting in
mesenteric lymphatic at the 6th h after reperfusion in mesenteric effer-
ent lymphatic increased by VIP. This indicates that VIP enhances the ef-
fective responses of gastroenteric tract as a result of the increased
number of intestinal lymphocytes generated from GALT to systemic cir-
culation and in turn homing to gastroenteric tract during early IIR inju-
ry, while the decreased proportion of 51Cr-intestinal lymphocytes
migration to gastroenteric tract after IIR injury treated with VIP does
not have a more crucial effect on these changes.
Mesenteric lymph pathway is an important bridge by which IIR
injury leads to SIRS and even MODS. VIP ameliorates intestinal inﬂam-
matory responses to IIR and improves the splanchnic organ function as-
sociated with mesenteric lymph pathway. This study emphasizes the
need to better understand the important roles of mesenteric lymph
pathway in protective effects of VIP on IIR induced multiple organ dys-
functions in rats. After IIR injury treated with VIP, the endotoxin and
TNF-α levels in mesenteric lymph were overall low and the number of
intestinal lymphocytes output in mesenteric efferent lymphatic obvi-
ously increased at the 6th h after reperfusion, suggesting that a suppres-
sion of gut-derived toxic mediators reaching the systemic circulation
and reinforcement of the effective immune responses in GALT may
need to be very aggressive to have beneﬁcial effects and ameliorate IIR
induced splanchnic organ damage at the early stage of IIR injury.
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